BLUE mit folgenden Beiträgen; (Um mal zu sehen wo so ihre Prioritäten liegen)
T. 3.00 – 5.00pm Engineering T Cells for Solid Tumor Applications, The End of The Beginning
• History and perspective of engineered T cells in solid tumor applications
• Do checkpoint antibody results point to paths forward?
• Overview of the tumor microenvironment (TME)
• What technologies can enhance engineered Tcell function in the TME?
Rick Morgan, Vice President of Immunotherapy, bluebird bio
--
W. 2.25 Viral Vector Engineering and Analytics
Gillian Payne, Director, Vector Analytics, bluebird bio
--
W. 5.15 PANEL: How Much Automation is Too Much Too Soon Given the Evolving Nature of the Technology?
Peter Olagunju, VP, Technical Operations, bluebird bio
Jim Faulkner, SVP, Head, Product Delivery, Autolus
Mike Stella, Chief Business Officer & Director, Cognate Bioservices
--
www.emedevents.com/c/...th-car-t-and-tcr-cell-immunotherapies
W. 3.00 CAR-T to TCR-T Success
Dolores Schendel, CEO & CSO, Medigene